BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24782504)

  • 21. Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia.
    Insuasti-Beltran G; Gale JM; Wilson CS; Foucar K; Czuchlewski DR
    Arch Pathol Lab Med; 2015 Aug; 139(8):1035-41. PubMed ID: 26230596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine.
    Abramenko I; Bilous N; Kryachok I; Filonenko I; Pilipenko G; Chumak A; Bazyka D; Bebeshko V
    Exp Oncol; 2007 Sep; 29(3):226-30. PubMed ID: 18004251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
    Martínez-Trillos A; Pinyol M; Delgado J; Aymerich M; Rozman M; Baumann T; González-Díaz M; Hernández JM; Alcoceba M; Muntañola A; Terol MJ; Navarro B; Giné E; Jares P; Beà S; Navarro A; Colomer D; Nadeu F; Colado E; Payer AR; García-Cerecedo T; Puente XS; López-Otin C; Campo E; López-Guillermo A; Villamor N
    Leuk Lymphoma; 2018 Oct; 59(10):2318-2326. PubMed ID: 29115891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.
    Sutton LA; Ljungström V; Mansouri L; Young E; Cortese D; Navrkalova V; Malcikova J; Muggen AF; Trbusek M; Panagiotidis P; Davi F; Belessi C; Langerak AW; Ghia P; Pospisilova S; Stamatopoulos K; Rosenquist R
    Haematologica; 2015 Mar; 100(3):370-6. PubMed ID: 25480502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.
    Young E; Noerenberg D; Mansouri L; Ljungström V; Frick M; Sutton LA; Blakemore SJ; Galan-Sousa J; Plevova K; Baliakas P; Rossi D; Clifford R; Roos-Weil D; Navrkalova V; Dörken B; Schmitt CA; Smedby KE; Juliusson G; Giacopelli B; Blachly JS; Belessi C; Panagiotidis P; Chiorazzi N; Davi F; Langerak AW; Oscier D; Schuh A; Gaidano G; Ghia P; Xu W; Fan L; Bernard OA; Nguyen-Khac F; Rassenti L; Li J; Kipps TJ; Stamatopoulos K; Pospisilova S; Zenz T; Oakes CC; Strefford JC; Rosenquist R; Damm F
    Leukemia; 2017 Jul; 31(7):1547-1554. PubMed ID: 27890934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia.
    Szymańska A; Bojarska-Junak A; Drobiecki A; Tomczak W; Roliński J; Hus M; Hus I
    Arch Immunol Ther Exp (Warsz); 2019 Feb; 67(1):55-65. PubMed ID: 30196472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Number of Overlapping AID Hotspots in Germline IGHV Genes Is Inversely Correlated with Mutation Frequency in Chronic Lymphocytic Leukemia.
    Yuan C; Chu CC; Yan XJ; Bagnara D; Chiorazzi N; MacCarthy T
    PLoS One; 2017; 12(1):e0167602. PubMed ID: 28125682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL.
    Morilla A; Gonzalez de Castro D; Del Giudice I; Osuji N; Else M; Morilla R; Brito Babapulle V; Rudenko H; Matutes E; Dearden C; Catovsky D; Morgan GJ
    Leuk Lymphoma; 2008 Nov; 49(11):2108-15. PubMed ID: 19021053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.
    Puente XS; Pinyol M; Quesada V; Conde L; Ordóñez GR; Villamor N; Escaramis G; Jares P; Beà S; González-Díaz M; Bassaganyas L; Baumann T; Juan M; López-Guerra M; Colomer D; Tubío JM; López C; Navarro A; Tornador C; Aymerich M; Rozman M; Hernández JM; Puente DA; Freije JM; Velasco G; Gutiérrez-Fernández A; Costa D; Carrió A; Guijarro S; Enjuanes A; Hernández L; Yagüe J; Nicolás P; Romeo-Casabona CM; Himmelbauer H; Castillo E; Dohm JC; de Sanjosé S; Piris MA; de Alava E; San Miguel J; Royo R; Gelpí JL; Torrents D; Orozco M; Pisano DG; Valencia A; Guigó R; Bayés M; Heath S; Gut M; Klatt P; Marshall J; Raine K; Stebbings LA; Futreal PA; Stratton MR; Campbell PJ; Gut I; López-Guillermo A; Estivill X; Montserrat E; López-Otín C; Campo E
    Nature; 2011 Jun; 475(7354):101-5. PubMed ID: 21642962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing.
    Vollbrecht C; Mairinger FD; Koitzsch U; Peifer M; Koenig K; Heukamp LC; Crispatzu G; Wilden L; Kreuzer KA; Hallek M; Odenthal M; Herling CD; Buettner R
    PLoS One; 2015; 10(6):e0129544. PubMed ID: 26053404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.
    Villamor N; Conde L; Martínez-Trillos A; Cazorla M; Navarro A; Beà S; López C; Colomer D; Pinyol M; Aymerich M; Rozman M; Abrisqueta P; Baumann T; Delgado J; Giné E; González-Díaz M; Hernández JM; Colado E; Payer AR; Rayon C; Navarro B; José Terol M; Bosch F; Quesada V; Puente XS; López-Otín C; Jares P; Pereira A; Campo E; López-Guillermo A
    Leukemia; 2013 Apr; 27(5):1100-6. PubMed ID: 23295735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential gene expression profile associated to apoptosis induced by dexamethasone in CLL cells according to IGHV/ZAP-70 status.
    Baptista MJ; Muntañola A; Calpe E; Abrisqueta P; Salamero O; Fernández E; Codony C; Giné E; Kalko SG; Crespo M; Bosch F
    Clin Cancer Res; 2012 Nov; 18(21):5924-33. PubMed ID: 22966019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
    Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
    Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative analysis of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia.
    Muñoz L; Lasa A; Carricondo MT; Hernández C; Ubeda J; Nomdedéu JF
    Cytometry B Clin Cytom; 2007 Mar; 72(2):96-102. PubMed ID: 17051526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the 3'UTR region of the NOTCH1 gene in chronic lymphocytic leukemia patients.
    Abramenko IV; Bilous NI; Chumak AA; Dyagil IS; Martina ZV
    Exp Oncol; 2018 Oct; 40(3):211-217. PubMed ID: 30284999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome.
    Brieghel C; da Cunha-Bang C; Yde CW; Schmidt AY; Kinalis S; Nadeu F; Andersen MA; Jacobsen LO; Andersen MK; Pedersen LB; Delgado J; Baumann T; Mattsson M; Mansouri L; Rosenquist R; Campo E; Nielsen FC; Niemann CU
    Clin Cancer Res; 2020 Mar; 26(6):1507-1515. PubMed ID: 31919133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.
    Hunter ZR; Yang G; Xu L; Liu X; Castillo JJ; Treon SP
    J Clin Oncol; 2017 Mar; 35(9):994-1001. PubMed ID: 28294689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrent gene mutations in CLL.
    Martínez-Trillos A; Quesada V; Villamor N; Puente XS; López-Otín C; Campo E
    Adv Exp Med Biol; 2013; 792():87-107. PubMed ID: 24014293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
    Rassenti LZ; Huynh L; Toy TL; Chen L; Keating MJ; Gribben JG; Neuberg DS; Flinn IW; Rai KR; Byrd JC; Kay NE; Greaves A; Weiss A; Kipps TJ
    N Engl J Med; 2004 Aug; 351(9):893-901. PubMed ID: 15329427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
    Bo MD; Del Principe MI; Pozzo F; Ragusa D; Bulian P; Rossi D; Capelli G; Rossi FM; Niscola P; Buccisano F; Bomben R; Zucchetto A; Maurillo L; de Fabritiis P; Amadori S; Gaidano G; Gattei V; Del Poeta G
    Ann Hematol; 2014 Oct; 93(10):1765-74. PubMed ID: 24923451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.